dextran-bound sulfonamide

used to demonstrate the presence of carbonic anhydrase activity in the extracellular space of rat hippocampal slices

Also Known As:

DBSA

Networked: 13 relevant articles (2 outcomes, 2 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Macromolecular Substances: 97
- Polymers: 13051
  - Biopolymers: 773
    - Glucans: 1624
      - Dextrans: 8114
        dextran-bound sulfonamide: 13
Carbohydrates: 22023
- Polysaccharides: 15383
  - Glucans: 1624
    - Dextrans: 8114
      - dextran-bound sulfonamide: 13
Organic Chemicals: 133
- Amides: 2428
  - Sulfonamides: 2809
    - dextran-bound sulfonamide: 13
- Sulfur Compounds: 278
  - Sulfones: 534
    - Sulfonamides: 2809
      - dextran-bound sulfonamide: 13

Experts

1.	Dou, Peipei: 1 article (08/2021)
2.	Han, Cuiping: 1 article (08/2021)
3.	Jiao, Min: 1 article (08/2021)
4.	Jin, Shang: 1 article (08/2021)
5.	Li, Jingjing: 1 article (08/2021)
6.	Li, Mengshuang: 1 article (08/2021)
7.	Luo, Tao: 1 article (08/2021)
8.	Wang, Yong: 1 article (08/2021)
9.	Wu, Changyu: 1 article (08/2021)
10.	Xu, Kai: 1 article (08/2021)

Related Diseases

1.	Brain Injuries (Brain Injury) 01/01/2018 - "Furthermore, DBSA administration reversed the protective effects of RACK1 overexpression against brain injury and decreased the expression of p-IRE1, XBP1 and GRP78. "
2.	Hypoxia (Hypoxemia) 02/01/2006 - "Safranin O uptake in reoxygenated tubules, which was decreased 85% after 60-min hypoxia, was normalized by dBSA, which improved ATP synthesis as well. " 02/01/2006 - "dBSA also almost completely normalized Deltapsi(m) when the duration of hypoxia was increased to 120 min. In intact tubules, the protective substrate combination of alpha-ketoglutarate + malate (alpha-KG/MAL) increased ATP three- to fourfold, limited NEFA accumulation during hypoxia by 50%, and lowered NEFA during reoxygenation. "
3.	Pancreatic Neoplasms (Pancreatic Cancer) 11/01/2020 - "In addition, the 'one-step'-synthesized dBSA-CuInS2/ZnS QDs have a long average fluorescence lifetime of 153.76 ns and a small particle size of 5 ± 2 nm. To demonstrate the applicability of the 'one-step'-synthesized dBSA-CuInS2/ZnS QDs in bioimaging studies, we modified the QDs with folic acid and hyaluronic acid, and then performed target bioimaging and cytotoxicity tests on macrophages, liver cancer cells and pancreatic cancer cells. "
4.	Liver Neoplasms (Liver Cancer) 11/01/2020 - "In addition, the 'one-step'-synthesized dBSA-CuInS2/ZnS QDs have a long average fluorescence lifetime of 153.76 ns and a small particle size of 5 ± 2 nm. To demonstrate the applicability of the 'one-step'-synthesized dBSA-CuInS2/ZnS QDs in bioimaging studies, we modified the QDs with folic acid and hyaluronic acid, and then performed target bioimaging and cytotoxicity tests on macrophages, liver cancer cells and pancreatic cancer cells. "
5.	Body Weight (Weight, Body) 10/01/2003 - "On a mg per kg of body weight dose basis, the no-observed-effect level doses for rats in the fertility study and rabbits in the developmental study were 2,000 and 4,000 (320 and 1,300 scaled to dose per unit body surface area [DBSA]) times that which a person would receive given 1 unit of treated blood. "

Related Drugs and Biologics

1.	Adenosine Triphosphate (ATP)
2.	Endoplasmic Reticulum Chaperone BiP
3.	safranine T (safranin)
4.	Hyaluronic Acid (Hyaluronan)
5.	Folic Acid (Vitamin M)
6.	Surface-Active Agents (Surfactants)
7.	Lidocaine (Xylocaine)
8.	Ketoglutaric Acids (Ketoglutaric Acid)
9.	Nonesterified Fatty Acids (NEFA)
10.	Doxorubicin (Adriamycin)

Related Therapies and Procedures

1.	Therapeutics